FDA approves Teva's Austedo for tardive dyskinesia

FDA approved Austedo deutetrabenazine (SD-809) from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) to treat tardive dyskinesia in adults. Austedo is already approved in the U.S. to treat chorea associated with Huntington’s disease (HD)...